USANA Health Sciences (NYSE:USNA) Releases FY 2026 Earnings Guidance

USANA Health Sciences (NYSE:USNA) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided EPS guidance of 0.760-0.760 for the period, compared to the consensus EPS estimate of 2.120. The company issued revenue guidance of $910.0 million-$910.0 million, compared to the consensus revenue estimate of $945.1 million.

USANA Health Sciences Stock Performance

Shares of USNA stock traded down $0.46 during trading on Thursday, hitting $14.54. 241,881 shares of the company were exchanged, compared to its average volume of 124,245. The firm has a market capitalization of $268.36 million, a price-to-earnings ratio of -11.91, a P/E/G ratio of 0.90 and a beta of 0.73. The business’s 50-day simple moving average is $20.55 and its 200 day simple moving average is $19.74. USANA Health Sciences has a twelve month low of $14.45 and a twelve month high of $32.32.

USANA Health Sciences (NYSE:USNA) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of $0.43 by ($0.50). USANA Health Sciences had a negative net margin of 2.43% and a positive return on equity of 3.40%. The company had revenue of $223.27 million during the quarter, compared to analyst estimates of $235.00 million. USANA Health Sciences has set its FY 2026 guidance at 0.760-0.760 EPS. On average, equities analysts forecast that USANA Health Sciences will post 2.12 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on USNA. Zacks Research lowered USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 22nd. Weiss Ratings restated a “sell (d)” rating on shares of USANA Health Sciences in a research note on Wednesday, June 24th. Finally, Wall Street Zen raised USANA Health Sciences from a “hold” rating to a “buy” rating in a research report on Saturday, June 20th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Reduce”.

Insider Transactions at USANA Health Sciences

In related news, CFO G Doug Iiekking sold 5,360 shares of the company’s stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $18.75, for a total value of $100,500.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director John Turman Fleming sold 2,450 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $17.93, for a total transaction of $43,928.50. Following the transaction, the director directly owned 4,230 shares in the company, valued at $75,843.90. The trade was a 36.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 13,869 shares of company stock worth $261,441 in the last 90 days. 0.82% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Russell Investments Group Ltd. grew its stake in USANA Health Sciences by 4.6% in the 4th quarter. Russell Investments Group Ltd. now owns 12,431 shares of the company’s stock valued at $244,000 after buying an additional 542 shares during the last quarter. First Trust Advisors LP acquired a new position in USANA Health Sciences during the 4th quarter worth $246,000. Wells Fargo & Company MN lifted its position in USANA Health Sciences by 37.9% during the 4th quarter. Wells Fargo & Company MN now owns 13,311 shares of the company’s stock worth $261,000 after acquiring an additional 3,655 shares during the last quarter. Brooklyn Investment Group bought a new stake in USANA Health Sciences during the fourth quarter valued at about $263,000. Finally, Intech Investment Management LLC grew its position in shares of USANA Health Sciences by 13.5% in the third quarter. Intech Investment Management LLC now owns 7,722 shares of the company’s stock valued at $213,000 after purchasing an additional 918 shares during the last quarter. Institutional investors and hedge funds own 54.25% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.